<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406717</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_10_33</org_study_id>
    <nct_id>NCT01406717</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in
      reducing blood glucose levels. The purpose of study is to establish safety and efficacy of
      SPIL1033
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPIL1033 is subcutaneous injection is indicated as adjunctive therapy to improve glycemic
      control in patients with type 2 diabetes mellitus.

      In this study, efficacy and safety of SPIL1033 will be evaluated. Subjects will receive
      SPIL1033 or placebo, 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the
      remaining 20 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects positive for anti-exenatide antibodies.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of potentially immune-related treatment-emergent adverse events will be evaluated.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's global impression of change.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Investigator's global impression of change will be recorded at end of trial or premature trial termination visit on a scale of 1-7 as follows:
Scale: Overall impression
Very much improved
Much improved
Minimally improved
No change
Minimally worse
Much worse
Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shifts in vital signs and other laboratory safety parameters from baseline to end-of-trial.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other (non-immune-related) treatment-emergent adverse events will be evaluated.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's global impression of change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subject's global impression of change will be recorded at end of trial or premature trial termination visit on a scale of 1-7 as follows:
Scale: Overall impression
Very much improved
Much improved
Minimally improved
No change
Minimally worse
Much worse
Very much worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SPIL1033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPIL1033, Placebo</intervention_name>
    <description>5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.</description>
    <arm_group_label>SPIL1033</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 20 years of age and older.

          -  Established clinical diagnosis of type 2 diabetes mellitus treated with diet and
             exercise or anti-diabetic agents as monotherapy or combination therapy.

          -  Weight stable: their weight should not have varied more than 10% of screening visit
             weight, within 6 months prior to screening visit.

          -  Women of child bearing potential practicing an acceptable method of birth control as
             judged by the investigator(s); with a negative urine pregnancy test.

          -  Willing to participate and give written informed consent.

        Exclusion Criteria:

          -  Previous exposure to exenatide (anti-exenatide antibodies at screening) or a GLP-1
             analogue.

          -  Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine,
             rimonabant, or similar over-the-counter medications) within 3 months of screening.

          -  Received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of trial entry.

          -  Severe renal impairment (creatinine clearance &lt;30 ml/min) or end stage renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Pharma Advanced Research Company Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPIL Site 22</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 25</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 26</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 23</name>
      <address>
        <city>Vishakhapatnam</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 1</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 2</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 3</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 5</name>
      <address>
        <city>Rajkot</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 6</name>
      <address>
        <city>Surat</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 7</name>
      <address>
        <city>Surat</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 8</name>
      <address>
        <city>Surat</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 9</name>
      <address>
        <city>Surat</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 10</name>
      <address>
        <city>Vadodara</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 19</name>
      <address>
        <city>Bangalore</city>
        <state>kARNATAKA</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 30</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 31</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 33</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 29</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 35</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 21</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 24</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 32</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 11</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 12</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 13</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Orrissa</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 14</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 15</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 34</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 16</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 17</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamilnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 20</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamilnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 18</name>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 27</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPIL Site 28</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>February 4, 2017</last_update_submitted>
  <last_update_submitted_qc>February 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPIL1033</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

